MoonLake Immunotherapeutics Class A share price logo

MoonLake Immunotherapeutics Class A

NASDAQ: MLTX

Small Cap

$19.21

+0.02

(+0.10%)

as on

MoonLake Immunotherapeutics Class A Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $19.00
    $19.80
    downward going graph

    1.09%

    Downside

    3.07%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.95
    $62.75
    downward going graph

    69.03%

    Downside

    226.65%

    Upside

    downward going graph

MoonLake Immunotherapeutics Class A share price movements today

Previous Close
$19.19
Open
$19.50
Volume
796.4K
Day's Low - High
$19.00 - $19.80
52 Week Low - High
$5.95 - $62.75

MoonLake Immunotherapeutics Class A Historical Returns

1 Month Return
+ 17.35 %
3 Month Return
+ 15.17 %
1 Year Return
-55.84 %
3 Year Return
-26.34 %
5 Year Return
0 %

MoonLake Immunotherapeutics Class A Stock Fundamentals & Key Indicators

Check MoonLake Immunotherapeutics Class A market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.4B

EPS (TTM)

-3.8585

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-264.3M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-77.85%

MoonLake Immunotherapeutics Class A vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MoonLake Immunotherapeutics Class A with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
MoonLake Immunotherapeutics Class A image
MoonLake Immunotherapeutics Class A
BUY$1.4BNANA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for MoonLake Immunotherapeutics Class A Stock including INR - Dollar returns

The MoonLake Immunotherapeutics Class A stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

MoonLake Immunotherapeutics Class A investment value today

Current value as on today

₹48,104

Returns

-₹51,896

(-51.9%)

Returns from MoonLake Immunotherapeutics Class A Stock

-₹55,839 (-55.84%)

Dollar Impact

₹3,943 (+3.94%)

Analyst Recommendation on MoonLake Immunotherapeutics Class A Stock

Based on 22 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 22 analysts, 81.82% of analysts recommend a 'BUY' rating for MoonLake Immunotherapeutics Class A. Average target price of $27.62

MoonLake Immunotherapeutics Class A Share Price Target

Get share price movements and forecasts by analysts on MoonLake Immunotherapeutics Class A.

What analysts predicted

30.45%UPSIDE

Target Price

$27.62

Current Price

$19.21

Analyzed by

22 Analysts

Target

$27.62

MoonLake Immunotherapeutics Class A target price $27.62, a slight upside of 30.45% compared to current price of $19.21. According to 22 analysts rating.

Indian Investors' Interest in MoonLake Immunotherapeutics Class A Stock

Search interest for MoonLake Immunotherapeutics Class A Stock has decreased by -23% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-23% versus previous 30 day period

MoonLake Immunotherapeutics Class A Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
0
-
-
0
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-15
-19
-30
-43
-49
-47
-60
-71
-65
-70
EBITDA
-15
-13
-24
-35
-45
-40
-53
-66
-60
-65
Interest Expense
3
3
-
-
-
0
2
3
1
2
Depreciation
0
0
0
0
1
0
0
0
0
0
Income Before Tax
-7
-13
-24
-36
-46
-40
-55
-70
-62
-69
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-7
-13
-24
-35
-45
-39
-55
-69
-62
-69
Net Profit Margin
-37678.97%
-69272.47%
0.00%
0.00%
-44776.15%
0.00%
0.00%
0.00%
0.00%
0.00%

MoonLake Immunotherapeutics Class A Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
Gross Profit
0
0
-1
-2
Operating Income
-65
-54
-143
-244
EBITDA
-65
-43
-119
-219
Interest Expense
0
-
-
7
Depreciation
0
0
1
2
Income Before Tax
-64
-43
-120
-229
Income Tax Expense
0
0
0
0
Net Income
-64
-36
-118
-227
Net Profit Margin
0.00%
0.00%
0.00%
0.00%

MoonLake Immunotherapeutics Class A Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-13
-24
-36
-45
-40
-56
-70
-63
-69
Operating Cash Flow
-14
-27
-25
-48
-38
-54
-44
-58
-66
Investing Cash Flow
-28
-87
58
-147
56
88
88
-29
0
Financing Cash Flow
50
0
0
0
73
-
0
72
30
Change in Cash
7
-115
32
-195
91
35
44
-16
-36

MoonLake Immunotherapeutics Class A Annual Cash Flow

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-53
-49
-44
-121
-229
Operating Cash Flow
-35
-55
-42
-116
-196
Investing Cash Flow
0
-32
-25
-205
202
Financing Cash Flow
43
119
479
51
145
Change in Cash
6
31
411
-270
154

Global Institutional Holdings in MoonLake Immunotherapeutics Class A

Funds
Holdings
BlackRock Inc
1.39%
Jefferies Financial Group Inc
0.69%
venBio Select Advisor LLC
2.79%
Nuveen, LLC
0.88%
Morgan Stanley - Brokerage Accounts
0.83%
See all

MoonLake Immunotherapeutics Class A News & Key Events

    Insights on MoonLake Immunotherapeutics Class A

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 6 months, MLTX stock has moved up by 43.5%

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 75.5%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, MoonLake Immunotherapeutics Class A Ordinary Shares has experienced a drawdown of -26.7%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 5.0%

    About MoonLake Immunotherapeutics Class A

    MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
    OrganisationMoonLake Immunotherapeutics Class A
    HeadquartersDorfstrasse 29, Zug, Switzerland, 6300
    IndustryBiotechnology
    CEODr. Jorge Santos da Silva Ph.D.
    E-voting on sharesClick here to vote

    Key Management of MoonLake Immunotherapeutics Class A

    Name

    Title

    Joana Cortez

    Associate Vice-President of Legal & Compliance

    Dr. Jorge Santos da Silva Ph.D.

    Co-Founder, Interim Chair of the Board & CEO

    Dr. Kristian Reich M.D., Ph.D.

    Co-Founder & Chief Scientific Officer

    Mr. Matthias Bodenstedt

    Chief Financial Officer

    Mr. Oliver Daltrop Ph.D.

    Chief Technical Officer

    Ms. Carla Bretes

    Director of Investor Relations & External Communications

    Mr. Nicolas Mosimann Ph.D.

    General Counsel

    Tino Anthamatten

    Vice President of Marketing, Market Access & Pricing

    Luciana Marques

    Associate Vice-President of HR, People and Culture

    Ms. Nuala Brennan

    Chief Clinical Development Officer

    FAQs

    What is MoonLake Immunotherapeutics Class A share price today?

    MoonLake Immunotherapeutics Class A share price today is $19.21 as on at the close of the market. MoonLake Immunotherapeutics Class A share today touched a day high of $19.8 and a low of $19.

    What is the 52 week high and 52 week low for MoonLake Immunotherapeutics Class A share?

    MoonLake Immunotherapeutics Class A share touched a 52 week high of $62.75 on and a 52 week low of $5.95 on . MoonLake Immunotherapeutics Class A stock price today i.e. is closed at $19.21,which is 69.39% down from its 52 week high and 222.86% up from its 52 week low.

    What is MoonLake Immunotherapeutics Class A's market capitalisation today?

    MoonLake Immunotherapeutics Class A market capitalisation is $0.00T as on .

    How to invest in MoonLake Immunotherapeutics Class A Stock (MLTX) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for MoonLake Immunotherapeutics Class A on INDmoney app. Click on Buy button. You can invest as low as $1.5 in MoonLake Immunotherapeutics Class A Shares that will get you 0.0781 shares as per MoonLake Immunotherapeutics Class A share price of $19.21 per share as on June 19, 2026 at 8:45 am IST.

    What is the minimum amount required to buy MoonLake Immunotherapeutics Class A Stock (MLTX) from India?

    Indian investors can start investing in MoonLake Immunotherapeutics Class A (MLTX) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹943.10 in MoonLake Immunotherapeutics Class A stock (as per the Rupee-Dollar exchange rate as on ). Based on MoonLake Immunotherapeutics Class A share’s latest price of $19.21 as on June 19, 2026 at 8:45 am IST, you will get 0.5206 shares of MoonLake Immunotherapeutics Class A. Learn more about fractional shares .